Intellia Therapeutics (NTLA) Stock Trends and Sentiment $22.66 +1.15 (+5.35%) (As of 02:19 PM ET) Add Compare Share Share Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Media Mentions Over Time2 Last Week 5 Current Week +150.0%View Trending Media Stocks MarketBeat New Followers Over Time1 Last Week 2 Current Week +100.0%View Trending Stocks on MarketBeat MarketBeat Searches Over Time0 Last Week 4 Current Week +400.0% Page Views Over Time849 Last Week 882 Current Week +3.9% WallStreetBets Posts Over Time0 Last Week 1 Current Week +100.0%View Trending WallStreetBets Stocks Recieve Intellia Therapeutics News and Ratings via Email Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Social Media Mentions Related Companies and Tools Related Companies: Celldex Therapeutics Stock Sentiment Editas Medicine Stock Sentiment CRISPR Therapeutics Stock Sentiment Sangamo Therapeutics Stock Sentiment Cellectis Stock Sentiment Intra-Cellular Therapies Stock Sentiment Elanco Animal Health Stock Sentiment Lantheus Stock Sentiment Revolution Medicines Stock Sentiment Ascendis Pharma A/S Stock Sentiment Trends Tools: Trending StocksTrending Media MentionsHigh Media Sentiment StocksTrending WallStreetBets StocksLive News Feed This page (NASDAQ:NTLA) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows th...Porter & Company | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
